[Low response rate to a vaccination against hepatitis B in patients with end-stage liver disease].

Hepatitis B vaccination was started in 41 patients with end-stage liver disease who were liver transplant candidates. Patients received three 20 microg or, starting from 1999, 40 microg doses of recombinant vaccine at 0, 2 and 4 weeks. Blood samples were obtained 4 weeks after vaccination or each revaccination; patients without protective hepatitis B surface antibodies (anti-HBs) were once or repeatedly revaccinated. Thirty-eight patients received at least 3 doses of vaccine. Protective anti-HBs level (≥ 10 IU/l) was detected in 17 of 34 patients (50 %) after the third up to eight dose. No case of chronic HBsAg carrier status was detected. Immunisation against hepatitis B in persons with liver cirrhosis is associated with a poor response and new vaccines should be considered for these patients.
AuthorsLuděk Rožnovský, Irena Orságová, Lenka Petroušová, Josef Tvrdík, Libuše Kabieszová, Martin Rydlo, Ivo Lochman, Alena Kloudová
JournalKlinická mikrobiologie a infekc̆ní lékar̆ství (Klin Mikrobiol Infekc Lek) Vol. 16 Issue 5 Pg. 179-81 (Oct 2010) ISSN: 1211-264X [Print] Czech Republic
Vernacular TitleMalá úcinnost vakcinace proti virové hepatitide B u pacientů s pokrocilým jaterním onemocnením.
PMID21191876 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Engerix-B
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines
  • Vaccines, Synthetic
  • Adult
  • Female
  • Hepatitis B (immunology, prevention & control)
  • Hepatitis B Antibodies (blood)
  • Hepatitis B Surface Antigens (blood)
  • Hepatitis B Vaccines (administration & dosage, immunology)
  • Humans
  • Immunization, Secondary
  • Liver Cirrhosis (immunology)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Vaccines, Synthetic
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: